Prospective Study on Embolization of Intracranial Aneurysms With Pipeline™ Embolization Device

Inclusion Criteria:

1. Subject has provided written informed consent using the IRB/EC-approved consent form
and agrees to comply with protocol requirements.

2. Age 22-80 years.

3. Subject has a target intracranial aneurysm (IA) located in the:

1. Internal carotid artery (up to the carotid terminus) OR

2. Vertebral artery segment up to and including the posterior inferior cerebellar
artery

4. Subject has a target IA that is ≤ 12 mm.

5. Subject has a target IA that has a parent vessel with diameter 1.5-5.0 mm
distal/proximal to the target IA.

6. Subject has a target IA with an aneurysm neck ≥ 4mm or a dome to neck ratio ≤ 1.5.

7. Subject has a pre-procedure PRU value between 60-200.

Exclusion Criteria:

1. Subject has received an intracranial implant (e.g. coils) in the area of the target
IA within the past 12 weeks.

2. Subarachnoid hemorrhage in the past 30 days.

3. Subject with anatomy not appropriate for endovascular treatment due to severe
intracranial vessel tortuosity or stenosis determined from baseline or pre-procedure
imaging, or a history of intracranial vasospasm not responsive to medical therapy.

4. Major surgery in the last 30 days.

5. History of irreversible bleeding disorder and/or subject presents with signs of
active bleeding.

6. Any known contraindication to treatment with the Pipeline™ device, including:

1. Stent is in place in the parent artery at the target IA location

2. Contraindication to dual antiplatelet therapy

3. Relative contraindication to angiography (e.g., serum creatinine >2.5 mg/dL,
allergy to contrast that cannot be medically controlled).

4. Known severe allergy to platinum or cobalt/chromium alloys.

5. Evidence of active infection at the time of treatment (e.g., fever with
temperature >38°C and/or WBC >1.5 109/L).

7. The Investigator determines that the health of the subject or the validity of the
study outcomes (e.g., high risk of neurologic events, worsening of clinical condition
in the last 30 days) may be compromised by the subject's enrollment.

8. Pregnant or breast-feeding women or women who wish to become pregnant during the
length of study participation.

9. Participating in another clinical trial during the follow-up period that could
confound the treatment or outcomes of this investigation.